372 related articles for article (PubMed ID: 25808524)
1. The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation.
Wu Q; Madany P; Akech J; Dobson JR; Douthwright S; Browne G; Colby JL; Winter GE; Bradner JE; Pratap J; Sluder G; Bhargava R; Chiosea SI; van Wijnen AJ; Stein JL; Stein GS; Lian JB; Nickerson JA; Imbalzano AN
J Cell Physiol; 2015 Nov; 230(11):2683-94. PubMed ID: 25808524
[TBL] [Abstract][Full Text] [Related]
2. Co-regulation of transcription by BRG1 and BRM, two mutually exclusive SWI/SNF ATPase subunits.
Raab JR; Runge JS; Spear CC; Magnuson T
Epigenetics Chromatin; 2017 Dec; 10(1):62. PubMed ID: 29273066
[TBL] [Abstract][Full Text] [Related]
3. Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cells.
Wu Q; Sharma S; Cui H; LeBlanc SE; Zhang H; Muthuswami R; Nickerson JA; Imbalzano AN
Oncotarget; 2016 May; 7(19):27158-75. PubMed ID: 27029062
[TBL] [Abstract][Full Text] [Related]
4. The Bromodomains of the mammalian SWI/SNF (mSWI/SNF) ATPases Brahma (BRM) and Brahma Related Gene 1 (BRG1) promote chromatin interaction and are critical for skeletal muscle differentiation.
Sharma T; Robinson DCL; Witwicka H; Dilworth FJ; Imbalzano AN
Nucleic Acids Res; 2021 Aug; 49(14):8060-8077. PubMed ID: 34289068
[TBL] [Abstract][Full Text] [Related]
5. SWI/SNF chromatin remodeling enzyme ATPases promote cell proliferation in normal mammary epithelial cells.
Cohet N; Stewart KM; Mudhasani R; Asirvatham AJ; Mallappa C; Imbalzano KM; Weaver VM; Imbalzano AN; Nickerson JA
J Cell Physiol; 2010 Jun; 223(3):667-78. PubMed ID: 20333683
[TBL] [Abstract][Full Text] [Related]
6. The BRG1 ATPase of human SWI/SNF chromatin remodeling enzymes as a driver of cancer.
Wu Q; Lian JB; Stein JL; Stein GS; Nickerson JA; Imbalzano AN
Epigenomics; 2017 Jun; 9(6):919-931. PubMed ID: 28521512
[TBL] [Abstract][Full Text] [Related]
7. SWI/SNF chromatin-remodeling enzymes Brahma-related gene 1 (BRG1) and Brahma (BRM) are dispensable in multiple models of postnatal angiogenesis but are required for vascular integrity in infant mice.
Wiley MM; Muthukumar V; Griffin TM; Griffin CT
J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25904594
[TBL] [Abstract][Full Text] [Related]
8. Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers.
Papillon JPN; Nakajima K; Adair CD; Hempel J; Jouk AO; Karki RG; Mathieu S; Möbitz H; Ntaganda R; Smith T; Visser M; Hill SE; Hurtado FK; Chenail G; Bhang HC; Bric A; Xiang K; Bushold G; Gilbert T; Vattay A; Dooley J; Costa EA; Park I; Li A; Farley D; Lounkine E; Yue QK; Xie X; Zhu X; Kulathila R; King D; Hu T; Vulic K; Cantwell J; Luu C; Jagani Z
J Med Chem; 2018 Nov; 61(22):10155-10172. PubMed ID: 30339381
[TBL] [Abstract][Full Text] [Related]
9. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
10. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1.
Oike T; Ogiwara H; Tominaga Y; Ito K; Ando O; Tsuta K; Mizukami T; Shimada Y; Isomura H; Komachi M; Furuta K; Watanabe S; Nakano T; Yokota J; Kohno T
Cancer Res; 2013 Sep; 73(17):5508-18. PubMed ID: 23872584
[TBL] [Abstract][Full Text] [Related]
11. Differential Expression of SWI/SNF Chromatin Remodeler Subunits Brahma and Brahma-Related Gene During Drug-Induced Liver Injury and Regeneration in Mouse Model.
Sinha S; Verma S; Chaturvedi MM
DNA Cell Biol; 2016 Aug; 35(8):373-84. PubMed ID: 27097303
[TBL] [Abstract][Full Text] [Related]
12. Exquisite Sensitivity to Dual BRG1/BRM ATPase Inhibitors Reveals Broad SWI/SNF Dependencies in Acute Myeloid Leukemia.
Rago F; Rodrigues LU; Bonney M; Sprouffske K; Kurth E; Elliott G; Ambrose J; Aspesi P; Oborski J; Chen JT; McDonald ER; Mapa FA; Ruddy DA; Kauffmann A; Abrams T; Bhang HC; Jagani Z
Mol Cancer Res; 2022 Mar; 20(3):361-372. PubMed ID: 34799403
[TBL] [Abstract][Full Text] [Related]
13. Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes.
Alpsoy A; Dykhuizen EC
J Biol Chem; 2018 Mar; 293(11):3892-3903. PubMed ID: 29374058
[TBL] [Abstract][Full Text] [Related]
14. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers.
Sun A; Tawfik O; Gayed B; Thrasher JB; Hoestje S; Li C; Li B
Prostate; 2007 Feb; 67(2):203-13. PubMed ID: 17075831
[TBL] [Abstract][Full Text] [Related]
16. SWI/SNF chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation.
Banine F; Bartlett C; Gunawardena R; Muchardt C; Yaniv M; Knudsen ES; Weissman BE; Sherman LS
Cancer Res; 2005 May; 65(9):3542-7. PubMed ID: 15867346
[TBL] [Abstract][Full Text] [Related]
17. Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression.
Reisman DN; Strobeck MW; Betz BL; Sciariotta J; Funkhouser W; Murchardt C; Yaniv M; Sherman LS; Knudsen ES; Weissman BE
Oncogene; 2002 Feb; 21(8):1196-207. PubMed ID: 11850839
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of SWI/SNF chromatin remodeling factor subunits modulates cisplatin cytotoxicity.
Kothandapani A; Gopalakrishnan K; Kahali B; Reisman D; Patrick SM
Exp Cell Res; 2012 Oct; 318(16):1973-86. PubMed ID: 22721696
[TBL] [Abstract][Full Text] [Related]
19. The reversible epigenetic silencing of BRM: implications for clinical targeted therapy.
Glaros S; Cirrincione GM; Muchardt C; Kleer CG; Michael CW; Reisman D
Oncogene; 2007 Oct; 26(49):7058-66. PubMed ID: 17546055
[TBL] [Abstract][Full Text] [Related]
20. Brg1 Controls the Expression of Pax7 to Promote Viability and Proliferation of Mouse Primary Myoblasts.
Padilla-Benavides T; Nasipak BT; Imbalzano AN
J Cell Physiol; 2015 Dec; 230(12):2990-7. PubMed ID: 26036967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
